MaaT Pharma and BIOASTER just entered into an agreement to investigate the potentiality to expand…
MaaT PharmaFebruary 16, 2017
Un pionnier mondial du transfert de microbiote fécal pour répondre aux besoins médicaux non-couverts
MaaT PharmaNovember 7, 2016
Bringing to market the first autologous faecal microbiotherapy to restore human-microbe symbiosis.
MaaT PharmaJune 2, 2016
MaaT Pharma was able to accelerate development of a GMP manufacturing in a record time.
MaaT PharmaApril 4, 2016
€10 million fundraising to pursues the development of the first worldwide autologous microbiotherapy solution
MaaT PharmaMarch 22, 2016
MaaT Pharma, which develops the first treatment using an autologous intestinal microbiota transplant is now…
MaaT PharmaFebruary 16, 2016
Important step in developing microbiome therapy for severe intestinal Dysbiosis.
MaaT PharmaJuly 24, 2015
